|drug1783||Hydroxychloroquine + lopinavir/ritonavir Wiki||1.00|
|drug1541||Five-days oseltamivir Wiki||1.00|
|drug2271||Macrolide administered for 3-5 days Wiki||1.00|
|drug1544||Fixed-duration Hydrocortisone Wiki||1.00|
|drug3952||Ten-days oseltamivir Wiki||1.00|
|drug3125||Protocolised mechanical ventilation strategy Wiki||1.00|
|drug2272||Macrolide administered for up to 14 days Wiki||1.00|
|drug2440||Moxifloxacin or Levofloxacin Wiki||1.00|
|drug3615||Shock-dependent hydrocortisone Wiki||1.00|
|drug3989||Therapeutic anticoagulation Wiki||0.71|
|drug4249||Vitamin C Wiki||0.27|
|drug1060||Convalescent plasma Wiki||0.21|
There is one clinical trial.
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infectionMeasure: Days alive and not receiving organ support in ICU Time: Day 21
Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)Measure: Health-related Quality of life assessment Time: 6 months
Description: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospitalMeasure: Destination at time of hospital discharge Time: Free text Day 90
Description: Antibiotic Domain specific outcomeMeasure: Occurrence of multi-resistant organism colonisation/infection Time: Day 90, censored at hospital discharge
Description: Antibiotic Domain specific outcomeMeasure: Occurrence clostridium difficile Time: Day 90, censored at hospital discharge
Description: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death Time: Day 90, censored at hospital discharge
Description: Antiviral Domain specific outcome. Only required at selected sites.Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens Time: Day 3, up to Day 7
Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpointMeasure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) Time: Day 90, censored at hospital discharge
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports